Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022

BUY
$144.95 - $152.29 $775,337 - $814,599
5,349 Added 38.64%
19,192 $2.9 Million
Q2 2022

Aug 15, 2022

BUY
$83.14 - $145.99 $115,564 - $202,926
1,390 Added 11.16%
13,843 $2.02 Million
Q1 2022

May 16, 2022

BUY
$110.08 - $142.92 $1.07 Million - $1.39 Million
9,734 Added 358.0%
12,453 $1.48 Million
Q4 2021

Feb 14, 2022

SELL
$99.73 - $148.48 $152,586 - $227,174
-1,530 Reduced 36.01%
2,719 $375,000
Q3 2021

Nov 15, 2021

BUY
$98.85 - $138.91 $420,013 - $590,228
4,249 New
4,249 $590,000
Q1 2021

May 14, 2021

SELL
$64.07 - $91.75 $697,466 - $998,790
-10,886 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$65.07 - $98.24 $708,352 - $1.07 Million
10,886 New
10,886 $933,000
Q2 2020

Aug 12, 2020

SELL
$29.01 - $74.23 $211,860 - $542,101
-7,303 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$27.51 - $57.29 $200,905 - $418,388
7,303 New
7,303 $249,000

Others Institutions Holding BHVN

About Biohaven Pharmaceutical Holding Co Ltd.


  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $2.8B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.